REFERENCES
1. Lin, Y.F., et al., Severe cutaneous adverse reactions related
to systemic antibiotics. Clin Infect Dis, 2014. 58 (10): p.
1377-85.
2. Phillips, E.J., et al., Controversies in drug allergy: Testing
for delayed reactions. J Allergy Clin Immunol, 2019. 143 (1):
p. 66-73.
3. Copaescu, A., et al., An Updated Review of the Diagnostic
Methods in Delayed Drug Hypersensitivity. Frontiers in Pharmacology,
2021. 11 (1928).
4. Johansen, J.D., et al., European Society of Contact Dermatitis
guideline for diagnostic patch testing - recommendations on best
practice. Contact Dermatitis, 2015. 73 (4): p. 195-221.
5. Trubiano, J.A., et al., The Combined Utility of Ex Vivo IFN-γ
Release Enzyme-Linked ImmunoSpot Assay and In Vivo Skin Testing in
Patients with Antibiotic-Associated Severe Cutaneous Adverse Reactions.J Allergy Clin Immunol Pract, 2018. 6 (4): p. 1287-1296.e1.
6. Copaescu, A., et al., The Role of In Vivo and Ex Vivo
Diagnostic Tools in Severe Delayed Immune-Mediated Adverse Antibiotic
Drug Reactions. J Allergy Clin Immunol Pract, 2021. 9 (5): p.
2010-2015.e4.
7. Trubiano, J.A., et al., Drug-specific upregulation of CD137 on
CD8+ T cells aids in the diagnosis of multiple antibiotic toxic
epidermal necrolysis. J Allergy Clin Immunol Pract, 2017.5 (3): p. 823-826.
8. Trubiano, J.A., et al., Analysis of Skin-Resident Memory T
Cells Following Drug Hypersensitivity Reactions. J Invest Dermatol,
2020. 140 (7): p. 1442-1445.e4.
9. Posadas, S.J., et al., Delayed reactions to drugs show levels
of perforin, granzyme B, and Fas-L to be related to disease severity. J
Allergy Clin Immunol, 2002. 109 (1): p. 155-61.
10. Tanvarasethee, B., S. Buranapraditkun, and J. Klaewsongkram,The Potential of Using ELISPOT to Diagnose Cephalosporin-induced
Maculopapular Exanthems. Acta dermato-venereologica, 2012. 93 .
11. Naranjo, C.A., et al., A method for estimating the probability
of adverse drug reactions. Clin Pharmacol Ther, 1981. 30 (2):
p. 239-45.
12. Bastuji-Garin, S., et al., SCORTEN: a severity-of-illness
score for toxic epidermal necrolysis. J Invest Dermatol, 2000.115 (2): p. 149-53.
13. Sassolas, B., et al., ALDEN, an algorithm for assessment of
drug causality in Stevens-Johnson Syndrome and toxic epidermal
necrolysis: comparison with case-control analysis. Clin Pharmacol Ther,
2010. 88 (1): p. 60-8.
14. Miyagawa, F. and H. Asada, Current Perspective Regarding the
Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome/Drug
Reaction with Eosinophilia and Systemic Symptoms (DIHS/DRESS). Int J
Mol Sci, 2021. 22 (4).
15. de Lima Moreira, M., et al., Hypersensitivities following
allergen antigen recognition by unconventional T cells. 2020.75 (10): p. 2477-2490.
16. Godfrey, D.I., et al., The burgeoning family of unconventional
T cells. Nat Immunol, 2015. 16 (11): p. 1114-23.
17. Kardaun, S.H., et al., Drug reaction with eosinophilia and
systemic symptoms (DRESS): an original multisystem adverse drug
reaction. Results from the prospective RegiSCAR study. Br J Dermatol,
2013. 169 (5): p. 1071-80.
18. Zavala, S., et al., How Does SCORTEN Score? J Burn Care Res,
2018. 39 (4): p. 555-561.
19. A., C., et al., Dose Dependent Antimicrobial
Cellular Cytotoxicity – Implications for ex vivo diagnostics.Frontiers in Pharmacolgy, 2021.
20. Reantragoon, R., et al., Antigen-loaded MR1 tetramers define T
cell receptor heterogeneity in mucosal-associated invariant T cells. J
Exp Med, 2013. 210 (11): p. 2305-20.
21. Corbett, A.J., et al., T-cell activation by transitory
neo-antigens derived from distinct microbial pathways. Nature, 2014.509 (7500): p. 361-5.